Drug intelligence / Profile preview

Irgen

Development stage: Unknown
Lead developer: Sugen Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Irgen** is an oral antenatal haematinic fixed-dose combination marketed by Sugen Pharma for pregnant women. Each tablet contains ferrous ascorbate 100 mg, folic acid 1 mg, cyanocobalamin 7.5 mcg, cholecalciferol 1000 IU, and zinc 10 mg. It is intended to replenish iron and vitamin cofactors needed for erythropoiesis and haemoglobin production, supporting prevention or treatment of iron deficiency anaemia during pregnancy.

Brand names: Irgen

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on Irgen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Irgen.

Explore the full profile